Clinical Trial Update: PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of PLX2853 in combination with Abiraterone acetate and prednisone, and in combination with Olaparib, for Metastatic Castration-Resistant Prost…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Olaparib (Olaparib)
• PLX-2853 (PLX2853)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Opna Bio LLC | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-04-08